Results 1 - 10 of 88 : 1 2 3 4 5 6 7 8 9 Next
5-Star Stocks Poised to Pop: Teva Pharmaceutical
Market-trouncing returns could be written in this 5-star.
A Top BioMarin Drug Heads Overseas
BioMarin's Kuvan is tentatively given the thumbs up in Europe.
A nod from the FDA and a new partnership boost Indevus shares. Where to, now?
It's conquering the world, slowly but surely. But is it still a value play?
Sanofi-Aventis finally wins a bidding war for a sought-after prize.
Ranbaxy's Troubles Won't Help Competitors
It may be hard to get a hit in with so much competition kicking Ranbaxy while it's down.
Teva and FDA's Never-Ending Court Battle
Teva looses latest battle against the FDA.
Some taxpayers enjoy a 0% rate on capital gains.
The drugmaker charts a different course for its future.
The generic-drug company decides to keep its specialty pharmaceutical subsidiary.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK